During the meeting on 19-20 May 2026, 21 consortium members and scientific advisors discussed recent progress across the programme. This included new exciting results from preclinical studies with vaccine candidates based on virus-like particles (VLPs), recombinant proteins and mRNA platforms, alongside results on the development of novel adjuvant systems to enhance immune responses.

UltiMalVax project partners and members of its scientific and ethics advisory committee (SEAC) met in Oxford on the 15th and 16th of May...

Project partners and members of SEAC met in Portugal to discuss progress, challenges and upcoming activities.

This would be a multi-species, multi-stage malaria vaccine to target malaria parasites found in Africa, Asia, and south America.